Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimen

Timothy E. Ritter, MD – Texas Digestive Disease Consultants, Southlake, TX, U.S.
Harry E. Sarles, MD – DHAT Research Institute, Garland, TX, U.S.
Robert C. McLeay, PhD – DoseMeRx, Brisbane, Australia
Lucinda J. Van Anglen, PharmD – Healix LLC, Sugar Land, TX, U.S.
Claudia P. Schroeder, PharmD, PhD – Healix LLC, Sugar Land, TX, U.S.

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.